Click here to open the filter panel
F
Fairness and transparency
F
Federated learning
F
Filing system
F
First-in-class drugs
F
Food and Drug Administration (FDA)
F
Fundamental rights impact assessment (FRIA)
G
General Data Protection Regulation (GDPR)
G
General-purpose AI model (GPAI)
G
Genetically modified organism (GMO)
G
Genetic data
G
Global public health security
G
Good clinical practice (GCP)
H
Health data warehouse (HDW)
H
High-risk AI system
H
HIPAA (Health Insurance Portability and Accountability Act)
H
Human oversight (AI Act)
H
Human subjects protection review board
I
Incapacitated subject
I
Information Commissioner's Office (ICO)
I
Informed consent
Click a letter to view all its definitions
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Term of the Day

Natural history study

A natural history study is a preplanned observational study intended to track the course of a disease over time, identifying demographic, genetic, environmental and other variables that correlate with its development and outcomes in the absence of intervention, or under standard of care. Designs may be retrospective (chart review of existing records) or prospective (longitudinal follow-up of a cohort or registry).

Natural history data is particularly important in rare and paediatric diseases, where randomised placebo-controlled trials may be infeasible or unethical. The FDA (guidance on rare disease natural history studies, 2019) and the EMA accept well-designed natural history studies to define endpoints and biomarkers, identify patient subgroups, estimate sample sizes and, in some cases, serve as external or historical control arms for single-arm trials supporting orphan products.

Because they are non-interventional, natural history studies fall outside the CTR and are governed by national law (for example France's MR-003 or MR-004 reference methodologies) and by the GDPR. They typically involve secondary use of medical records, long-term follow-up, genetic data and small populations in which anonymisation is rarely achievable, so pseudonymisation, a DPIA and a robust research legal basis under Art. 9(2)(j) are essential. Registries maintained by patient organisations or academic consortia raise additional questions of joint controllership and data access governance.

U

UK GDPR

The UK GDPR is the version of the EU General Data Protection Regulation retained in United Kingdom law after Brexit under the European Union (Withdrawal) Act 2018, as modified by the Data Protection, Privacy and Electronic Communications (Amendments etc.) (EU Exit) Regulations 2019. It applies since 1 January 2021 together with the Data Protection Act 2018, which supplements it with UK-specific provisions on special category data conditions (Schedule 1), exemptions, law enforcement and intelligence processing. The Data (Use and Access) Act 2025 introduced targeted amendments, including recognised legitimate interests, a statutory definition of scientific research, relaxed rules for automated decision-making outside special category data, and a reformed regulator.

The substance mirrors the EU GDPR: the same principles, legal bases, rights, DPIA and DPO requirements, breach notification and fine levels (up to GBP 17.5 million or 4% of turnover). Key differences lie in enforcement by the Information Commissioner's Office (to become the Information Commission), in the UK's own adequacy regulations (which recognise the EEA and other countries), in UK transfer tools (the International Data Transfer Agreement and the UK Addendum to the EU SCCs, plus the UK Extension to the Data Privacy Framework), and in Art. 3A, which requires controllers and processors outside the UK that offer goods or services to, or monitor, people in the UK to appoint a UK representative.

For life sciences, the UK remains a major trial location, and clinical trials there are regulated by the Medicines for Human Use (Clinical Trials) Regulations 2004 as reformed in 2025, with the Health Research Authority overseeing ethics. A sponsor running trials in both the EU and the UK therefore needs two representatives, two transfer analyses and dual references in its informed consent forms and records. The European Commission renewed the UK's EU adequacy decisions in December 2025, so EU-to-UK transfers remain free of additional safeguards. iliomad acts as UK Data Protection Representative; see also the UK Data Protection Act service page.